Today’s pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for COVID-19 vaccines. However, the industry’s major underlying drivers — higher rates of cancer and chronic diseases — are still at play.
Year-to-date gain: 384.54 percent; market cap: US$241.51 million; share price: US$4.70
First up on this top-performing NASDAQ pharma stocks list is Rezolute Bio, a clinical-stage company that is developing therapeutic candidates geared at treating metabolic and orphan diseases.
Market cap: US$483.83 million; year-to-date gain: 220.82 percent; share price: US$1.88
Biotechnology firm Ocugen is developing and commercializing novel gene and cell therapies and vaccines with a focus on the treatment of eye, orthopedic and infectious diseases. Its product pipeline includes OCU400, a therapy with a gene-agnostic mechanism of action.
The continuous news flow helped Ocugen’s share price rally from the end of February to reach a year-to-date high of US$1.98 on May 16.
Year-to-date gain: 201.54 percent; market cap: US$68.05 million; share price: US$1.90
Entera Bio is developing orally delivered peptides and small therapeutic proteins for indications such as osteoporosis, hyperparathyroidism and short bowel syndrome. The company’s proprietary N-Tab technology oral delivery platform prevents the degradation of and enhances the bioavailability of these peptides and therapeutic proteins.
Year-to-date gain: 168.97 percent; market cap: US$94.3 million; share price: US$2.34
SEED is looking to early 2025 to file an investigational new drug (IND) application for its oral RBM39 degrader candidate for cancer indications. Eli Lilly is an investor and collaborator of SEED.
Year-to-date gain: 151.73 percent; market cap: US$261.31 million; share price: US$1.42
Last on this list of the year’s top-performing NASDAQ pharma stocks is Nektar Therapeutics, which is developing medicines in the fields of immunotherapy and oncology.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Leave a Reply